Literature DB >> 30890427

GDF11 exhibits tumor suppressive properties in hepatocellular carcinoma cells by restricting clonal expansion and invasion.

Monserrat Gerardo-Ramírez1, Roberto Lazzarini-Lechuga2, Sharik Hernández-Rizo1, Javier Esteban Jiménez-Salazar2, Arturo Simoni-Nieves1, Carmen García-Ruiz3, José Carlos Fernández-Checa3, Jens U Marquardt4, Cedric Coulouarn5, María Concepción Gutiérrez-Ruiz6, Benjamín Pérez-Aguilar7, Luis E Gomez-Quiroz8.   

Abstract

Growth differentiation factor 11 (GDF11) has been characterized as a key regulator of differentiation in cells that retain stemness features, despite some controversies in age-related studies. GDF11 has been poorly investigated in cancer, particularly in those with stemness capacity, such as hepatocellular carcinoma (HCC), one of the most aggressive cancers worldwide. Here, we focused on investigating the effects of GDF11 in liver cancer cells. GDF11 treatment significantly reduced proliferation, colony and spheroid formation in HCC cell lines. Consistently, down-regulation of CDK6, cyclin D1, cyclin A, and concomitant upregulation of p27 was observed after 24 h of treatment. Interestingly, cell viability was unchanged, but cell functionality was compromised. These effects were potentially induced by the expression of E-cadherin and occludin, as well as Snail and N-cadherin repression, in a time-dependent manner. Furthermore, GDF11 treatment for 72 h induced that cells were incapable of sustaining colony and sphere capacity in the absent of GDF11, up to 5 days, indicating that the effect of GDF11 on self-renewal capacity is not transient. Finally, in vivo invasion studies revealed a significant decrease in cell migration of hepatocellular carcinoma cells treated with GDF11 associated to a decreased proliferation judged by Ki67 staining. Data show that exogenous GDF11 displays tumor suppressor properties in HCC cells.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell cycle; GDF11; HCC; Hep3B cells; Huh7 cells; Liver cancer

Year:  2019        PMID: 30890427     DOI: 10.1016/j.bbadis.2019.03.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  7 in total

1.  GDF-11 promotes human trophoblast cell invasion by increasing ID2-mediated MMP2 expression.

Authors:  Ze Wu; Lanlan Fang; Sizhu Yang; Yibo Gao; Zhen Wang; Qingxue Meng; Xuan Dang; Ying-Pu Sun; Jung-Chien Cheng
Journal:  Cell Commun Signal       Date:  2022-06-15       Impact factor: 7.525

2.  GDF11 prevents the formation of thoracic aortic dissection in mice: Promotion of contractile transition of aortic SMCs.

Authors:  Kai Ren; Buying Li; Zhenhua Liu; Lin Xia; Mengen Zhai; Xufeng Wei; Weixun Duan; Shiqiang Yu
Journal:  J Cell Mol Med       Date:  2021-03-25       Impact factor: 5.310

Review 3.  GDF11 Implications in Cancer Biology and Metabolism. Facts and Controversies.

Authors:  Arturo Simoni-Nieves; Monserrat Gerardo-Ramírez; Gibrán Pedraza-Vázquez; Lisette Chávez-Rodríguez; Leticia Bucio; Verónica Souza; Roxana U Miranda-Labra; Luis E Gomez-Quiroz; María Concepción Gutiérrez-Ruiz
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

Review 4.  Tight Junction Proteins and the Biology of Hepatobiliary Disease.

Authors:  Natascha Roehlen; Armando Andres Roca Suarez; Houssein El Saghire; Antonio Saviano; Catherine Schuster; Joachim Lupberger; Thomas F Baumert
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

5.  Exosome-transmitted miR-3124-5p promotes cholangiocarcinoma development via targeting GDF11.

Authors:  Huijie Gao; Zhaobin He; Chao Gao; Naiqing Liu; Zhaoyang Zhang; Weibo Niu; Jun Niu; Cheng Peng
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

Review 6.  Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?

Authors:  Jan Frohlich; Manlio Vinciguerra
Journal:  Geroscience       Date:  2020-10-06       Impact factor: 7.713

7.  GDF11 induces mild hepatic fibrosis independent of metabolic health.

Authors:  Jan Frohlich; Kristina Kovacovicova; Tommaso Mazza; Maria R Emma; Daniela Cabibi; Michelangelo Foti; Cyril Sobolewski; Jude A Oben; Marion Peyrou; Francesc Villarroya; Maurizio Soresi; Rita Rezzani; Melchiorre Cervello; Francesca Bonomini; Anna Alisi; Manlio Vinciguerra
Journal:  Aging (Albany NY)       Date:  2020-10-28       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.